탈모 시장 규모, 점유율 및 동향 분석 보고서 : 질병 유형별, 치료법별, 성별, 판매 채널별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), By Treatment, By Gender, By Sales Channel, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,206,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,585,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,343,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

탈모 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 탈모 세계 시장 규모는 2024년부터 2030년까지 CAGR 9.1%를 기록하여 2030년에는 160억 2,000만 달러에 달할 것으로 예상됩니다.

JAK 억제제와 티로신 키나아제 억제제의 승인과 대상 질환의 유병률 증가가 시장 성장의 원동력이 될 것으로 예상됩니다.

전 세계적으로 원형 탈모(AA) 및 전두 탈모의 유병률이 증가하고 있으며, 2023년 3 월에 발표 된 연구 논문에 따르면 미국과 영국에서 피부과 클리닉에서 새로 발생하는 사례의 0.6 % - 2 %가 원형 탈모이라고합니다. 전 세계적으로 실시된 병원 기반 조사에서 원형탈모 발생률은 0.57%에서 3.8%로 추정됩니다.

새로운 표적 치료제의 승인은 탈모 시장의 성장을 촉진하는 중요한 요인입니다. 예를 들어, 2022년 6월 미국 FDA는 릴리의 Olumiant 경구용 정제를 성인 환자의 중증 탈모 치료제로 승인하여 승인된 최초의 전신 치료제가 되었으며, 2023년에 승인될 것으로 예상되는 또 다른 중요한 약물은 화이자의 리트레시티닙입니다. 이것은 야누스 키나아제 3(JAK3)과 티로신 키나아제의 이중 억제제입니다.

산업 성장을 촉진하는 또 다른 중요한 요인은 탈모에 대한 인식의 증가와 이로 인한 전 세계 치료율의 상승입니다. 외모에 대한 인식 수준이 높아진 것이 치료를 받으려는 사람들이 증가하는 주요 이유 중 하나입니다. 또한, 연구개발 및 자금 조달에 대한 투자가 증가하고 있는 것도 시장 성장을 촉진하고 있습니다.

기초 질환을 치료할 수 있는 표적 치료제의 가용성이 제한적이라는 점은 이 시장의 중요한 과제 중 하나입니다. 표적 치료 기전을 가진 신제품이 승인되고 있지만, 이미 승인된 제품 대비 높은 약품 가격이 보급을 저해하는 주요 요인 중 하나입니다.

탈모 시장 보고서 하이라이트

• 등록 전 단계에 있는 Pfizer의 Ritlecitinib, 임상 2상 단계에 있는 Bioniz Therapeutics의 BNZ-1과 같은 파이프라인 제품의 승인이 임박함에 따라 2024년부터 2030년까지 원형탈모 분야가 가장 빠르게 성장할 것으로 예상됩니다.
• 2023년 시장은 북미가 지배적이었는데, 이는 주로 높은 소비자 인식, 기술 발전, 대상 질환 인구, 의료비 지출이 많았기 때문입니다.
• 아시아태평양은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이는 주로 대상 질환 인구의 증가와 질병 치료율의 증가에 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 탈모 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 탈모 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
• 가격 분석

제4장 탈모 시장 : 질환 추정·동향 분석

• 질환 유형 시장 점유율, 2023년 및 2030년
• 부문 대시보드
• 질환별 세계의 탈모 시장 전망

제5장 탈모 시장 : 치료 추정·동향 분석

• 치료 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 치료별 세계의 탈모 시장 전망

제6장 탈모 시장 : 성별 추정·동향 분석

• 성별 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 성별 세계 탈모 시장 전망

제7장 탈모 시장 : 판매 채널 추정·동향 분석

• 판매 채널 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 판매 채널별 세계의 탈모 시장 전망

제8장 탈모 시장 : 최종 용도 추정·동향 분석

• 최종 용도 시장 점유율, 2023년 및 2030년
• 부문 대시보드
• 최종 용도별 세계의 탈모 시장 전망

제9장 탈모 시장 : 지역 추정·동향 분석

• 지역 시장 점유율 분석, 2023년 및 2030년
• 지역 시장 대시보드
• 세계의 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 회사/경쟁 분류
• 벤더 상황
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • Janssen Global Services Inc.
  • Cipla Limited
  • Merck &Co., Inc.
  • GlaxoSmithKline plc
  • Sun Pharmaceuticals Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Aurobindo Pharma
  • Viatris Inc.
  • Pfizer, Inc.
  • Lilly
  • Lexington Intl., LLC(Devices)
  • Freedom Laser Therapy(iRestore ID-520 helmet)
  • Curallux, LLC.
  • Apira Science Inc.(iGROW Laser)
  • Revian Inc.
  • Theradome
  • Lutronic

ksm

영문 목차

영문목차

Alopecia Market Growth & Trends:

The global alopecia market size is expected to reach USD 16.02 billion by 2030, registering a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.

The prevalence of alopecia areata (AA) and alopecia totalis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.

The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly's Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer's Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.

Another key factor driving the industry's growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.

The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.

Alopecia Market Report Highlights:

• The alopecia universalis segment is expected to witness the fastest growth from 2024 to 2030, owing to the impending approval of pipeline products, such as Pfizer's Ritlecitinib which is in the pre-registration phase, and Bioniz Therapeutics's BNZ-1 which is in phase 2 clinical trials
• North America dominated the market in 2023, mainly due to the high consumer awareness, technological advancements, high target disease population, and high healthcare spending
• Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be majorly attributed to the rising target disease population and rising treatment rate for the disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Treatment
  • 1.2.3. Gender
  • 1.2.4. Sales Channel
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease Type
  • 2.2.2. Treatment
  • 2.2.3. Gender
  • 2.2.4. Sales Channel
  • 2.2.5. End Use
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing global prevalence of alopecia
    • 3.2.1.2. Increasing global healthcare expenditure
    • 3.2.1.3. Increasing prevalence of chronic diseases
    • 3.2.1.3.1. PCOS
    • 3.2.1.3.2. Cancer
    • 3.2.1.3.3. Rheumatoid Arthritis
    • 3.2.1.4. Technological advancements in alopecia treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of reimbursement policies for alopecia treatment
    • 3.2.2.2. Increasing adoption of substitutes
• 3.3. Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis

Chapter 4. Alopecia Market: Disease Type Estimates & Trend Analysis

• 4.1. Disease Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Alopecia Market by Disease Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Alopecia Areata
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Male
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Female
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cicatricial Alopecia
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Male
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Female
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Traction Alopecia
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.2. Male
    • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.3. Female
    • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Alopecia Totalis
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Male
    • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Female
    • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Alopecia Universalis
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Male
    • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Female
    • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Androgenetic Alopecia
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.2. Male
    • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.3. Female
    • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Others
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.2. Male
    • 4.4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.3. Female
    • 4.4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Alopecia Market: Treatment Estimates & Trend Analysis

• 5.1. Treatment Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Alopecia Market by Treatment Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Pharmaceuticals
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Topical
    • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.2. OTC
    • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.2.2. Minoxidil
    • 5.4.1.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.2.3. Others
    • 5.4.1.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3. Prescription
    • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3.2. Betamethasone Dipropionate
    • 5.4.1.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3.3. Fluocinolone Acetonide
    • 5.4.1.2.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3.4. Finasteride
    • 5.4.1.2.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3.5. Minoxidil
    • 5.4.1.2.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Oral
    • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.2. OTC
    • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3. Prescription
    • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3.2. Minoxidil
    • 5.4.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3.3. Finasteride
    • 5.4.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3.4. Corticosteroids
    • 5.4.1.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3.5. Others (JAK inhibitors and others)
    • 5.4.1.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.4. PRP
    • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Devices
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laser Cap
    • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.2. Laser Comb
    • 5.4.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.4. Laser Helmet
    • 5.4.2.2.5. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Alopecia Market: Gender Estimates & Trend Analysis

• 6.1. Gender Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Alopecia Market by Gender Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Prescriptions
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Female
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Alopecia Market: Sales Channel Estimates & Trend Analysis

• 7.1. Sales Channel Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Alopecia Market by Gender Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Prescription
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. OTC
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Alopecia Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Alopecia Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Homecare Settings
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.4.2. Dermatology Clinics
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Alopecia Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Mexico
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/ reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Janssen Global Services Inc.
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Cipla Limited
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Merck & Co., Inc.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. GlaxoSmithKline plc
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Sun Pharmaceuticals Industries Ltd
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Dr. Reddy's Laboratories Ltd
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Aurobindo Pharma
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Viatris Inc.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Pfizer, Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Lilly
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Lexington Intl., LLC (Devices)
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Freedom Laser Therapy (iRestore ID-520 helmet)
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Curallux, LLC.
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. Apira Science Inc. (iGROW Laser)
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. Revian Inc.
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives
  • 10.3.19. Theradome
    • 10.3.19.1. Company overview
    • 10.3.19.2. Financial performance
    • 10.3.19.3. Product benchmarking
    • 10.3.19.4. Strategic initiatives
  • 10.3.20. Lutronic
    • 10.3.20.1. Company overview
    • 10.3.20.2. Financial performance
    • 10.3.20.3. Product benchmarking
    • 10.3.20.4. Strategic initiatives

관련자료